Compare XHR & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XHR | CDNA |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | N/A | 765 |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2014 | 2007 |
| Metric | XHR | CDNA |
|---|---|---|
| Price | $20.25 | $28.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $15.67 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 1.0M | 901.4K |
| Earning Date | 05-01-2026 | 04-28-2026 |
| Dividend Yield | ★ 3.48% | N/A |
| EPS Growth | ★ 326.67 | N/A |
| EPS | ★ 0.21 | 0.05 |
| Revenue | ★ $1,078,500,000.00 | $48,324,000.00 |
| Revenue This Year | $3.94 | $16.01 |
| Revenue Next Year | $2.68 | $11.31 |
| P/E Ratio | ★ $96.90 | $583.80 |
| Revenue Growth | 3.80 | ★ 18.93 |
| 52 Week Low | $11.75 | $10.96 |
| 52 Week High | $20.83 | $30.00 |
| Indicator | XHR | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 66.71 | 70.95 |
| Support Level | $14.26 | $14.59 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.47 | 1.43 |
| MACD | -0.04 | 0.39 |
| Stochastic Oscillator | 73.77 | 88.86 |
Xenia Hotels & Resorts Inc is a real estate investment trust that invests in premium full-service, lifestyle, and urban upscale hotels and resorts across the United States. The company owns and pursues hotels in the upscale, upper upscale, and luxury segments that are affiliated with various brands. Its hotels are operated by Marriott, along with Hilton, Hyatt, Starwood, Kimpton, Aston, Fairmont, and Loews. The firm's properties are located in various regions across the U.S.: the South Atlantic, West South Central, Pacific, Mountain, and other regions. Xenia's revenue is divided between the sale of rooms, food and beverages, and other sources.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.